Conventus Orthopaedics Acquires Flower Orthopedics

Conventus Orthopaedics, Inc. has completed the acquisition of Flower Orthopedics, the market leader in Ready-for-Surgery™ single-use, sterile-packaged, implant and instrument kits. The news was announced today (May 27, 2020).

The state-of-the-art sterile FlowerCube™ system eliminates expensive set processing, which enables surgical facilities to complete back-to-back cases, enhance efficiencies, and maximize resources.  In addition to a robust fixation portfolio, Flower’s continuum of care also extends into the fast-growing wound care market for both orthopedic & podiatric surgeons.

Conventus Orthopaedics pioneered the platform nitinol CAGE technology to treat proximal humerus and distal radius fractures with unmatched stability & reduced complications compared to plating.  The Conventus lower extremity CAGE™ implant system is currently in development along with a new and innovative distal fibula intramedullary nailing system.  Both are expected to accelerate time to weight-bearing while reducing complications.

Rick Epstein, Chief Executive Officer of Conventus, commented, “Flower is an excellent strategic fit with Conventus.  With ongoing concerns over viral and infection risks associated with heavy reusable orthopedic implant trays, Flower’s Ready-for-Surgery™ platform reduces exposure to bioburden while enhancing OR efficiencies.  We will continue to develop and acquire innovative products and companies that improve procedures, patient outcomes and safety for orthopedic and foot & ankle surgeons.”

Andrew ElBardissi, MD, Partner at Deerfield Management stated that, “We are excited about the progress that Conventus has made over the past year. With the acquisition of Flower Orthopedics, we believe the company is positioned to be a leader in the development of innovative orthopedic technologies. We look forward to supporting the company’s continued growth.”

Conventus intends to continue to aggressively pursue new and innovative orthopedic technologies that are clinically relevant to surgeons, hospitals, and ambulatory surgery centers.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”